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than 25% of the primary tumor. Heterologous elements are tissue
types, such as skeletal muscle or cartilage, present in the neoplasm
and not native to the primary site. Here, we report two cases of cervical
MA, one with sarcomatous overgrowth and another with heterologous
elements.
Case 1 — cervical mullerian adenosarcoma with
sarcomatous overgrowthA 54-year-old woman presented to her gynecologist with acute uri-IntroductionMullerian adenosarcomas (MAs) are malignant mixed mullerian
tumors with benign epithelial and malignant stromal components that
most often originate in the endometrium (71%), ovary (15%), or pelvis
(12%), and less frequently develop in the cervix (2%) (Clement and
Scully, 1974, 1990; Verschraegen et al., 1998). MAs behave as low-
grade malignancies with a proclivity for local recurrence; distant
metastases are infrequent (Clement and Scully, 1990; Verschraegen
et al., 1998). Cervical MAs usually present as cervical polyps and can
be confused with benign cervical polyps both clinically and pathologi-
cally; microscopic differentiation is critical for accurate diagnosis and
appropriate treatment. Since cervical MAs are rare, experience with
their diagnosis and treatment is limited. Due to a paucity of reports
and an absence of long term follow-up data, the presentation, prognosis
and management of cervical MA continue to be explored.
Two types of MA with unusual pathologic features are associated
with poorer prognoses: MA with sarcomatous overgrowth and MA
with heterologous elements. Sarcomatous overgrowth is diagnosedGynecology, and Reproductive
y, CT 06810, USA. Fax: +1 203
i).
c. This is an open access article undernary retention. She reported irregularmenses for the past four years. She
was a former smoker, had a remote history ofmyomectomy, and had no
family history of any cancer. On examination, she had a distended abdo-
men and suprapubic tenderness. Pelvic examination revealed a large
cervical mass which appeared to originate from the endocervical
canal. Tumor markers were as follows: CA 125 = 127 U/ml, CEA =
0.7 ng/ml, and CA19-9=52 U/ml. Computed tomography demonstrat-
ed an 8 cm heterogeneousmass involving the cervix without extension
of tumor into the bladder or rectum (Fig. 1A). No signiﬁcant lymphade-
nopathy was noted. Exam under anesthesia found an 8 cm smooth,
ﬁrm, and hemorrhagic mass with a broad base involving the cervix.
The parametria were free. A prominent left ovary was palpated.
Cystoscopy and proctoscopy were unremarkable. Cervical biopsies
were performed and demonstrated ﬁbrovascular tissue with severe
hemorrhage.
The patient was counseled extensively, and she decided to undergo
radical hysterectomy and bilateral salpingo-oophorectomy with frozen
section, which was of concern for cervical sarcoma. Bilateral pelvic
and para-aortic lymph node dissection was performed and all 27
identiﬁed nodes were negative for malignancy. Final pathology con-
ﬁrmed cervical low gradeMAwith sarcomatous overgrowthmeasuring
4 × 3 × 2 cm (Fig. 2 and Supplemental Information 1). Tumor immuno-
histochemistrywas diffusely positive formusclemarkers SMA andMSA,
as well as estrogen and progesterone receptors, and focally positive for
desmin, CKAE1/3, and CAM 5.2, but negative for myogenin, EMA, CD10,
caldesmon, HMB-45, CD31, CD34, factor VIII, inhibin, and S100. She
received adjuvant vaginal cuff brachytherapy (25 Gy of iridium-192)the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Fig. 1. A: Representative computed tomography sagittal image of large cervical mullerian
adenosarcoma with sarcomatous overgrowth (Case 1). B: Representative magnetic
resonance sagittal image, T2 weighted, of large cervical mullerian adenosarcoma with
heterologous elements (Case 2).
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recovery and adjuvant treatment courses were uncomplicated. She
remains without evidence of disease now 66 months after diagnosis of
her stage IB2 cervical MA with sarcomatous overgrowth.Fig. 2. A: Gross pathologic specimen. B: Tumor glands within collagenous stroma. C: Low
power ﬁeld showing benign glands with stromal condensation. D: High power ﬁeld
showing benign glands with stromal condensation.Case 2 — cervical mullerian adenosarcoma with
heterologous elements
A 47-year-old woman with no gynecologic care for many years
presentedwith irregular vaginal bleeding. Her pastmedical and surgical
histories included hypertension, obesity, cholecystectomy, and a unilat-
eral oophorectomy for an unknown benign indication. Physical exami-
nation revealed a 10 cm polypoid, partially necrotic cervical mass
arising from a pedicle in the endocervical canal. Assessment of the uter-
us and adnexa was very limited secondary to body habitus. Exam under
anesthesia further revealed bilateral shortening of the parametria. Cys-
toscopy and proctoscopy were negative for bladder or rectal involve-
ment. Cervical biopsies demonstrated cervical adenosarcoma with a
histologically high grade stromal component having rhabdomyoblastic
differentiation (Fig. 3 and Supplemental Information 1). Magnetic reso-
nance imaging demonstrated a 9.5 cm× 9.6 cm× 8.1 cm cervical tumor
with bilateral inﬁltration of the parametria and right parametrial lymph
nodes (Fig. 1B), without evidence of abdominal or lung metastases.
Given her stage IIB disease, initial treatment was preoperative
whole pelvis external beam radiation (5040 cGy) and chemotherapyconsisting of three cycles of ifosfamide (2000 mg/m2) and doxorubicin
(40mg/m2). Signiﬁcant toxicity of this treatment included colitis neces-
sitating a four-day hospitalization, during which interval computed
tomography showed an ill-deﬁned cervical mass, new enlargement of
the uterus, abdominal carcinomatosis andmultiple pulmonarymetasta-
ses. Chemotherapy was changed to gemcitabine (675 mg/m2) and
docetaxel (75 mg/m2). Repeat imaging after 3 cycles demonstrated
disease progression. She began palliative docetaxel (35 mg/m2) for
two additional cycles before electing for comfort care only. She subse-
quently died due to metastatic cervical MA 12 months after diagnosis.
Discussion
MAs are generally low grade neoplasms that may recur locally after
initial surgical resection and infrequently metastasize to distal sites.
Fig. 3. A: Biphasic cervical malignant neoplasm with atypical glands and high-grade spindle cell sarcomatous elements (H&E stain, magniﬁcation ×100). B: Area of atypical
glands with mild nuclear pleomorphism and focal squamoid features (H&E stain, magniﬁcation ×400). C: Region of undifferentiated sarcoma with round cell morphology
(H&E stain, magniﬁcation ×100). D: Area of high-grade sarcoma with rhabdoid morphology, including polygonal and strap-shaped tumor cells with eccentric nuclei and abundant
eosinophilic cytoplasm with vague cross-striations (H&E stain, magniﬁcation ×400).
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mitotic rate, sarcomatous overgrowth, heterologous elements, deep
myometrial invasion, necrosis and extrauterine spread (Jones and
Lefkowitz, 1995; Kerner and Lichtig, 1993; Kaku et al., 1992). The diag-
nosis of MA is established by the criteria proposed by Clement and
Scully (Clement and Scully, 1990) and Jones and Lefkowitz (Jones and
Lefkowitz, 1995): formation of periglandular cuffs and intraglandular
protrusions of cellular stroma, non-invasive glands lined by benign-
appearing mullerian epithelia of various types showing mild to marked
nuclear atypia, an average of ≥2 mitotic ﬁgures per 10 high powered
ﬁelds in the stromal component, and more than mild nuclear atypia
of the stromal cells. Given the rarity of this disease, we recommend
a pathology review by a national expert when the diagnosis of
adenosarcoma is suspected or uncertain. The clinical behavior and path-
ologic features of Case 2 were suggestive of carcinosarcoma. A patholo-
gy review by a leading national expert in adenosarcoma was obtained.
The expertwas conﬁdent in the diagnosis of a high grade adenosarcoma
with rhabdomyoblastic differentiation, which was suggested to be a
feature associated with relatively aggressive disease, although reported
clinical experience with this entity is insufﬁcient to provide robust
prognostic information.
Approximately 2% of MAs develop in the cervix. In the largest series
of cervical MA (24 cases), the mean age at presentation was 31 years
(range 11–65 years), with one-third of patients presenting before age
15 (Jones and Lefkowitz, 1995). Most patients presentedwith abnormal
vaginal bleeding and a polypoid appearing lesion protruding through
the external cervical os. The differential diagnosis of cervical MA
includes benign (adenoﬁbroma, atypical endocervical polyp, and
adenomyoma of the cervix) and malignant (uterine adenosarcoma
with secondary involvement of the cervix, carcinosarcoma, and
embryonal rhabdomyosarcoma) lesions. Nine cases of cervical MA
with sarcomatous overgrowth (Table S1) and eighteen cases of MA
with heterologous elements (Table S2) are reported in the literature.
Four cases had both sarcomatous overgrowth and heterologous
elements (Table S1). The most common heterologous elements are
skeletal muscle and cartilage.The prognosis and management of cervical MA continue to be
deﬁned as the number of reported cases increases.Much of themanage-
ment of cervical MA is extrapolated from experience with uterine MAs,
which, while uncommon among uterine cancers, are seen much more
frequently than cervical MAs. Some authors recommend hysterectomy
and bilateral salpingo-oophorectomy (Clement and Scully, 1990; Gast
et al., 1989; Zaloudek andNorris, 1981). Local excision has been curative
in rare cases (Table S2). Fertility sparing surgery may be an alternative
in patients with pedunculated cervical tumors with uninvolved stalks
(Clement and Scully, 1990; Chen, 1985). However, obtaining a negative
margin is necessary, and reoperation should be considered when dis-
ease extends to the surgical margins (Michener and Simon, 2001). No
standard of care exists for radiation or chemotherapy of uterine or cer-
vicalMAdue to lack of evidence that any particular therapy ismore ben-
eﬁcial than other options in reported series (Krivak et al., 2001; Tanner
et al., 2013; Bernard et al., 2013). Adjuvant treatment recommendations
are poorly deﬁned. Cases 1 and 2 were managed with radiation and
standard sarcoma chemotherapy regimens that are among many treat-
ment options per National Comprehensive Cancer Network guidelines
(Annon, 2014). Management options for uterine sarcomas have been
recently reviewed (Reichardt, 2012; Trope et al., 2012). Trials of radia-
tion or chemotherapy for uterine sarcomas often included multiple
uterine sarcoma types, such as the early GOG trial of stage I–II uterine
sarcomas that randomized patients to adjuvant doxorubicin or no
further treatment and showed no statistically signiﬁcant beneﬁt but
did establish a precedent for use of adjuvant doxorubicin for uterine
sarcomas (Omura et al., 1985). Retrospective data suggested decreased
recurrence with radiation therapy, but no beneﬁt was found in a pro-
spective trial (Reed et al., 2008). Adenosarcomas with sarcomatous
overgrowth are often treated according to guidelines for high-grade un-
differentiated endometrial sarcoma (Trope et al., 2012). In Case 1, vaginal
brachytherapy and single agent doxorubicin were offered due to the
presence of sarcomatous overgrowth. Case 2 was stage IIB and high
grade. The patient received second opinions regarding treatment options
and electedwhole pelvic radiation and one of themost studied combina-
tion chemotherapies for uterine sarcomas (ifosfamide/doxorubicin),
10 B.-L.L. Seagle et al. / Gynecologic Oncology Reports 9 (2014) 7–10with a plan for post-treatment surgery. Due to early disease progres-
sion with systemic metastases, she was switched to combination
gemcitabine/docetaxel, which is preferred for advanced or recurrent
leiomyosarcoma (NCCN, 2014). Her disease continued to progress and
she began palliative docetaxel before electing for comfort measures only.
Recurrences after 5 years are not infrequent for uterine MAs; there-
fore long-term clinical follow-up is recommended (Clement and Scully,
1990; Jones and Lefkowitz, 1995; Zaloudek and Norris, 1981). A local
recurrence rate of 24% and a distant recurrence rate of 2% after hysterec-
tomy and bilateral salpingo-oophorectomy were reported with recur-
rences occurring between 0.5 and 9.5 years; one-third of recurrences
occurred after 5 years (Clement and Scully, 1990). In GOG 40, Kaku
et al. (1992) reported a 30% recurrence rate of uterine MAs, with most
recurrences occurring within 24 months after hysterectomy, bilateral
salpingo-oophorectomy, and lymph node sampling. One series com-
pared survival of patients diagnosed with uterine adenosarcoma with
sarcomatous overgrowth (N = 11) to survival of patients with uterine
carcinosarcoma (N = 33), reporting a trend toward worse prognosis
of uterine MA with sarcomatous overgrowth (p = 0.052) with a medi-
an survival of 13 months (Krivak et al., 2001). A recent small (N=5) se-
ries of uterineMAwith sarcomatous overgrowth reported a 20% 2-year
survival rate (Tanner et al., 2013). The prognosis of cervical MA with
sarcomatous overgrowth or heterologous elements remains less charac-
terized. Cases need to be reported as only continued accumulation of
clinicopathologic data will lead to improved understanding of this
disease. Here we report two cases of large cervical MA tumors with
contrasting clinical outcomes: one case of stage IB2 low grade cervical
MA with sarcomatous overgrowth and long-term disease free survival
after surgical resection, vaginal brachytherapy, and single-agent chemo-
therapy and the second case being a patient with stage IIB high grade
cervical MA with rhabdomyoblastic differentiation who experienced a
short 12 month disease speciﬁc survival despite whole pelvic external
beam radiation andmultiple courses of chemotherapy. The disease pro-
gression of Case 2wasmore rapid than is typical of MAs andmay repre-
sent a more aggressive nature of high gradeMAwith rhabdomyoblastic
features: more reports of clinical outcomes of patients with this rare
histologic feature are needed to establish its prognostic signiﬁcance.
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